达拉非尼联合曲美替尼对比达拉非尼单药治疗转移性BRAF V600E/K突变黑色素瘤:3期研究的长期生存与安全性分析
COMBI-d 3期双盲研究纳入423例既往未治疗的BRAF V600E/K突变不可切除IIIC期或IV期黑色素瘤患者,随机接受达拉非尼联合曲美替尼(n=211)或达拉非尼单药(n=212)。联合组3年无进展生存率为22%对单药组12%,3年总生存率为44%对32%,长期安全性与此前观察一致,未发现新安全性信号。
要点
- 联合组3年无进展生存率22%,单药组12%;3年总生存率联合组44%,单药组32%。
- 联合组3年总生存率在有利亚组(乳酸脱氢酶正常且转移器官部位<3个)达62%,不利亚组(乳酸脱氢酶升高)仅25%。
- 联合治疗安全性与此前临床试验观察一致,长期使用未检测到新的安全性信号。
核心结论
- 达拉非尼联合曲美替尼在BRAF V600突变转移性黑色素瘤患者中可实现持久(≥3年)生存,支持该联合方案在此情形下长期一线使用。
研究设计与样本
- COMBI-d(NCT01584648)是一项双盲3期研究,纳入既往未治疗的BRAF V600E/K突变不可切除IIIC期或IV期黑色素瘤患者。
- 2012年5月4日至11月30日期间,947例筛查患者中共423例随机分配到达拉非尼联合曲美替尼组(n=211)或达拉非尼单药组(n=212)。
- 患者随机接受达拉非尼(150 mg每日两次)联合曲美替尼(2 mg每日一次)或达拉非尼联合安慰剂。
- 主要终点为无进展生存期,次要终点为总生存期、总体缓解、缓解持续时间、安全性和药代动力学。
主要发现
- 数据截止(2016年2月15日)时,联合组结局仍优于单药组:3年无进展生存率联合组22%对单药组12%。
- 3年总生存率联合组44%对单药组32%。
- 25例单药组患者交叉至联合治疗,仍按意向治疗原则在单药组下继续随访。
- 联合组3年时仍存活的患者中,58%仍在接受达拉非尼联合曲美替尼治疗。
- 联合组3年总生存率在有利亚组(乳酸脱氢酶正常且转移器官部位<3个)达62%,在不利亚组(乳酸脱氢酶升高)仅25%。
关键数值与推荐
- 联合组3年无进展生存率22%,单药组12%。
- 联合组3年总生存率44%,单药组32%。
- 联合组有利亚组3年总生存率62%,不利亚组25%。
- 联合组3年时仍存活者中58%仍在接受联合治疗。
临床怎么用
- 原文结论支持达拉非尼联合曲美替尼在此情形下长期一线使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma. This study was continued to assess 3-year landmark efficacy and safety after ≥36-month follow-up for all living patients. PATIENTS AND METHODS: This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant unresectable stage IIIC or stage IV melanoma. Patients were randomized to receive dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) or dabrafenib plus placebo. The primary endpoint was PFS; secondary endpoints were OS, overall response, duration of response, safety, and pharmacokinetics. RESULTS: Between 4 May and 30 November 2012, a total of 423 of 947 screened patients were randomly assigned to receive dabrafenib plus trametinib (n = 211) or dabrafenib monotherapy (n = 212). At data cut-off (15 February 2016), outcomes remained superior with the combination: 3-year PFS was 22% with dabrafenib plus trametinib versus 12% with monotherapy, and 3-year OS was 44% versus 32%, respectively. Twenty-five patients receiving monotherapy crossed over to combination therapy, with continued follow-up under the monotherapy arm (per intent-to-treat principle). Of combination-arm patients alive at 3 years, 58% remained on dabrafenib plus trametinib. Three-year OS with the combination reached 62% in the most favourable subgroup (normal lactate dehydrogenase and <3 organ sites with metastasis) versus only 25% in the unfavourable subgroup (elevated lactate dehydrogenase). The dabrafenib plus trametinib safety profile was consistent with previous clinical trial observations, and no new safety signals were detected with long-term use. CONCLUSIONS: These data demonstrate that durable (≥3 years) survival is achievable with dabrafenib plus trametinib in patients with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting.
引用
- Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017. PMID: 28475671. doi:10.1093/annonc/mdx176
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。